Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Viatris and Theravance Report COPD Therapy Effective in China Phase III Trial

publication date: Nov 14, 2023

Pittsburgh’s Viatris and Theravance of Dublin reported positive results from a China Phase III trial of their partnered maintenance therapy for COPD.  Yupelri® (revefenacin) is a once-daily nebulized long-acting muscarinic antagonist (LAMA). It works by inhibiting the M3 receptor on smooth muscle, causing bronchodilation. The Phase III placebo-controlled trial showed a statistically significant increase in trough FEV1 (forced expiratory volume in one second) versus placebo, meeting the primary efficacy endpoint. A low FEV1 suggests a breathing obstruction. Viatris has operations in Shanghai in addition to those in the US and India. More details....

Stock Symbols: (NSDQ: VTRS) (NSDQ: TBPH)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital